ArticleNature communications2021
Targeting the latent human cytomegalovirus reservoir for T-cell-mediated killing with virus-specific nanobodies.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 51 citations in OpenAlex.
- Review
- Targeted next-generation sequencing-based pathogens detection in children with severe pneumonia in the pediatric intensive care unit.Frontiers in pediatrics · 2026Article
- Distinct Immunological Landscapes of HCMV-Specific T Cells in Bone Marrow and Peripheral Blood.Pathogens (Basel, Switzerland) · 2025Article
- Review
- Why Are Cytomegalovirus-Encoded G-Protein-Coupled Receptors Essential for Infection but Only Variably Conserved?Pathogens (Basel, Switzerland) · 2025Review
- Antibodies expand the scope of angiotensin receptor pharmacology.Nature chemical biology · 2024Article
- Virus-Specific Nanobody-Chimeras Degrade the Human Cytomegalovirus US28 Protein in CD34+ Cells.Pathogens (Basel, Switzerland) · 2024Article
- Delivery of US28 by incoming HCMV particles rapidly attenuates Akt activity to suppress HCMV lytic replication in monocytes.Science signaling · 2024Article
- Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine.NPJ vaccines · 2024Article
- Repurposing an endogenous degradation domain for antibody-mediated disposal of cell-surface proteins.EMBO reports · 2024Article
- Nanobodies: Robust miniprotein binders in biomedicine.Advanced drug delivery reviews · 2023Review
- The High Presence of HCMV pp71 Proteins, Correlate with P63 Expression in Pancreatic Cancer Tumor Tissue.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Metagenomic-based pathogen surveillance for children with severe pneumonia in pediatric intensive care unit.Frontiers in public health · 2023Article
- Therapeutic targeting of HCMV-encoded chemokine receptor US28: Progress and challenges.Frontiers in immunology · 2023Review
- Metagenomic Next-Generation Sequencing for the Diagnosis of Neonatal Infectious Diseases.Microbiology spectrum · 2022Article
- Functional and molecular dissection of HCMV long non-coding RNAs.Scientific reports · 2022Article
- Viral G Protein-Coupled Receptors Encoded by β- and γ-Herpesviruses.Annual review of virology · 2022Review
- The Chemokine System in Oncogenic Pathways Driven by Viruses: Perspectives for Cancer Immunotherapy.Cancers · 2022Review
- Research progress and applications of nanobody in human infectious diseases.Frontiers in pharmacology · 2022Review
- Recent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
Abstract
Latent human cytomegalovirus (HCMV) infection is characterized by limited gene expression, making latent HCMV infections refractory to current treatments targeting viral replication. However, reactivation of latent HCMV in immunosuppressed solid organ and stem cell transplant patients often results in morbidity. Here, we report the killing of latently infected cells via a virus-specific nanobody (VUN100bv) that partially inhibits signaling of the viral receptor US28. VUN100bv reactivates immediate early gene expression in latently infected cells without inducing virus production. This allows recognition and killing of latently infected monocytes by autologous cytotoxic T lymphocytes from HCMV-seropositive individuals, which could serve as a therapy to reduce the HCMV latent reservoir of transplant patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.